Measuring diffuse metabolic activity on FDG-PET/CT: New method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma

Nuclear Medicine and Biology

Volumn 39, Issue 3, 2012, Pages 429-436

  Szturz, Petr ^a   Řehák, Zdeněk ^b   Koukalová, Renata ^b   Adam, Zdeněk ^a   Krejčí, Marta ^a   Pour, Luděk ^a   Zahradová, Lenka ^a   Vaníček, Jiří ^c   Nebeský, Tomáš ^a   Hájek, Roman ^a   Mayer, Jiří ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

High resolution computed tomography (HRCT); Interstitial lung disease; Langerhans cell histiocytosis; Positron emission tomography; Pulmonary function tests

Indexed keywords

CLADRIBINE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; VINBLASTINE;

ADULT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HISTIOCYTOSIS X; HUMAN; LIVER PARENCHYMA; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON INVASIVE MEASUREMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PULMONARY HISTIOCYTOSIS X; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LUNG; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84858150614     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.10.002     Document Type: Article

References (20)

1. Vassallo R., Ryu J.H. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med 2004, 25(3):561-571.
2. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006, 27(6):1272-1285.
3. Sundar K.M., Gosselin M.V., Chung H.L., Cahill B.C. Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest 2003, 123(5):1673-1683.
4. Thomeer M., Demedts M., Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg 2001, 56(3):163-172. VRGT Working Group on Interstitial Lung Diseases.
5. Gaensler E.A., Carrington C.B. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients. Ann Thorac Surg 1980, 30(5):411-426.
6. Colby T.V., Lombard C. Histiocytosis X in the lung. Hum Pathol 1983, 14(10):847-856.
7. Watanabe R., Tatsumi K., Hashimoto S., Tamakoshi A., Kuriyama T. Clinico-epidemiological features of pulmonary histiocytosis X. Intern Med 2001, 40(10):998-1003. Respiratory Failure Research Group of Japan.
8. Vassallo R., Ryu J.H., Colby T.V., Hartman T., Limper A.H. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000, 342(26):1969-1978.
9. Schönfeld N., Frank W., Wenig S., Uhrmeister P., Allica E., Preussler H., et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 1993, 60(1):38-44.
10. Mogulkoc N., Veral A., Bishop P.W., Bayindir U., Pickering C.A., Egan J.J. Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999, 115(5):1452-1455.
11. Friedman P.J., Liebow A.A., Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore) 1981, 60(6):385-396.
12. Tomashefski J.F., Khiyami A., Kleinerman J. Neoplasms associated with pulmonary eosinophilic granuloma. Arch Pathol Lab Med 1991, 115(5):499-506.
13. Derenzini E., Fina M.P., Stefoni V., Pellegrini C., Venturini F., Broccoli A., et al. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol 2010, 21(6):1173-1178.
14. Phillips M., Allen C., Gerson P., McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009, 52(1):97-101.
15. Ribeiro M.J., Idbaih A., Thomas C., Remy P., Martin-Duverneuil N., Samson Y., et al. 18F-FDG PET in neurodegenerative Langerhans cell histiocytosis: results and potential interest for an early diagnosis of the disease. J Neurol 2008, 255(4):575-580.
16. Krajicek B.J., Ryu J.H., Hartman T.E., Lowe V.J., Vassallo R. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest 2009, 135(6):1542-1549.
17. Hoetjes N.J., van Velden F.H., Hoekstra O.S., Hoekstra C.J., Krak N.C., Lammertsma A.A., et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging 2010, 37(9):1679-1687.
18. Iozzo P., Geisler F., Oikonen V., Mäki M., Takala T., Solin O., et al. 18F-FDG PET Study. Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET Study. J Nucl Med 2003, 44(5):682-689.
19. Kubota K., Watanabe H., Murata Y., Yukihiro M., Ito K., Morooka M., et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nucl Med Biol 2011, 38(3):347-351.
20. Lin C.Y., Ding H.J., Lin C.C., Chen C.C., Sun S.S., Kao C.H. Impact of age on FDG uptake in the liver on PET scan. Clin Imaging 2010, 34(5):348-350.